Pfizer, Inc. Common is under Algo Engine buy conditions.
reported its Q1 2026 financial results on May 5, 2026, delivering a beat on both top and bottom lines as the company continues its transition away from peak pandemic-era revenues. Operational revenue from “launched and acquired products” surged 22%, driven by strong performance in the oncology and specialty care portfolios.
You're not a member! Trial today
Q1 2026 Earnings Summary
- Adjusted EPS: $0.75 (Beat consensus estimate of $0.72 by $0.03).
- Total Revenue: $14.45 billion (Beat estimate of ~$13.84 billion; up 5% year-over-year).
- Operational Growth: 2% (Excluding COVID-19 products, operational revenue grew 7%).
- GAAP EPS: $0.47 (Down from $0.52 in Q1 2025).
- Full-Year Revenue: $59.5 billion – $62.5 billion.
- Adjusted Diluted EPS: $2.80 – $3.00.
